Majority of panelists on controversial new cholesterol guideline have current or recent ties to drug manufacturers

BMJ (Clinical research ed.)

Volumn 347, Issue , 2013, Pages f6989-

  Lenzer, Jeanne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASES; COMPLICATION; CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS; HUMAN; HYPERCHOLESTEROLEMIA; PHYSICIAN; PRACTICE GUIDELINE;

CARDIOVASCULAR DISEASES; CONFLICT OF INTEREST; DRUG INDUSTRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PHYSICIANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84893520208     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f6989     Document Type: Note

References (0)